They treated three patients with recurrent glioblastoma using a variant of an existing CAR-T therapy, adding additional antibodies to the treatment — and the results were truly astounding.
According to the paper published in The New England Journal of Medicine, one patient saw their tumor decrease in size by 18.5% two days after the treatment, and by day 69, the tumor had decreased by 60.7%, while another saw their ‘tumor regress rapidly’, according to Mass General Brigham.
After the third patient was treated, an MRI showed that a single infusion had led to a ‘near-complete tumor regression’ in just five days.
Comments are closed.